Riyadh – Mubasher: Jamjoom Pharmaceuticals Factory Company (Jamjoom Pharma) rolled out its new corporate brand identity, marking the next phase of its strategic evolution towards being a leading global player in the pharmaceutical industry.
The new identity anchors the company’s objectives to boost its product portfolio, enhance quality without compromise, and promote regional partnerships, according to a press release.
Jamjoom Pharma operates in more than 36 countries across the Middle East and Africa, with core operations in Saudi Arabia, the UAE, Iraq, Levant, Egypt, and North Africa.
The group is a key provider of high-quality, trusted medicines and consumer healthcare products across multiple therapeutic areas, including ophthalmology, dermatology, cardiometabolic diseases, general medicine, and consumer health, amongst others.
Tarek Hosni, CEO of Jamjoom Pharma, said: "Our new identity is a clear statement of who we serve and why we exist - our patients. We believe everyone deserves access to trusted medicine and the chance to live a better life.”
Meanwhile, the company continues to scale capacity and efficiency across its four manufacturing facilities in the region to meet the demand and support the growth strategy.
Its management outlined a roadmap to sustain growth through new product launches, entry into high-prevalence therapeutic areas, and targeted investments across the MEA region.
Last September, Jamjoom Pharma penned a deal with Bio-Thera Solutions Limited to commercialize BAT2306 across the MENA region.
In terms of profitability, the company delivered an excellent net profit of SAR 289 million during the first half of 2025, with a margin of 34%.
